Page last updated: 2024-12-05

beta-hydroxymyristic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Beta-hydroxymyristic acid (BHMA) is a saturated fatty acid with a hydroxyl group at the beta-position. It is a major component of the lipids found in the myelin sheath, a fatty substance that insulates nerve fibers. BHMA plays a crucial role in maintaining the structural integrity and stability of the myelin sheath. Studies have shown that BHMA can also exhibit anti-inflammatory and antioxidant properties. Research on BHMA is focused on understanding its role in myelin formation and its potential therapeutic applications in neurological disorders such as multiple sclerosis.'

beta-hydroxymyristic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-hydroxytetradecanoic acid : A 3-hydroxy fatty acid that is tetradecanoic (myristic) acid substituted at position 3 by a hydroxy group [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16064
CHEMBL ID4456892
CHEBI ID85148
SCHEMBL ID142895
MeSH IDM0054964

Synonyms (51)

Synonym
1961-72-4
(+/-)-3-hydroxytetradecanoic acid
(rs)-3-hydroxytetradecanoic acid
beta-hydroxytetradecanoic acid
3-hydroxytetradecanoic acid
3-hydroxymyristic acid
tetradecanoic acid, 3-hydroxy-
3-hydroxy-tetradecanoic acid
beta-hydroxymyristic acid
(3rs)-3-hydroxytetradecanoic acid
tetradecanoic acid, 3-hydroxy- (6ci,7ci,8ci,9ci)
LMFA01050175
dl-beta-hydroxymyristic acid, >=98%
brn 1725372
F98D6745-6EF1-4182-BB79-6FB77737B72C
FT-0669879
FT-0669877
H0274
3-03-00-00660 (beilstein handbook reference)
unii-fl8s7f2jjq
fl8s7f2jjq ,
3422-31-9
FT-0625445
FT-0615850
SCHEMBL142895
beta-hydroxy-myristic acid
CHEBI:85148
.beta.-hydroxytetradecanoic acid
.beta.-hydroxymyristic acid
3-hydroxymyristic acid, (+/-)-
(+/-)-3-hydroxymyristic acid
dl-beta-hydroxymyristic acid
mfcd00059633
z6x ,
dl-b-hydroxymyristic acid
3-hydroxymyristic acid (racemic)
AKOS027380549
AS-58639
CHEMBL4456892 ,
J-019508
Q27158359
DTXSID20941380
4,6-dinitro-1,3-benzenedicarbonylchloride
T72017
bdbm50511033
SB47509
dl- beta -hydroxymyristic acid
STARBLD0000280
BAA96172
CS-W010260
HY-W009544
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
3-hydroxy fatty acidAny fatty acid with a hydroxy functional group in the beta- or 3-position. beta-Hydroxy fatty acids accumulate during cardiac hypoxia, and can also be used as chemical markers of bacterial endotoxins.
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
3-hydroxy monocarboxylic acidA hydroxy monocarboxylic acid that has a hydroxy group beta to the carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 84Homo sapiens (human)Ki0.51100.02361.29013.3100AID1546369
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 84Homo sapiens (human)EC50 (µMol)1.00100.08903.868710.0000AID1546364; AID1546366
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
biological_processG-protein coupled receptor 84Homo sapiens (human)
neuropeptide signaling pathwayG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
urotensin II receptor activityG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
specific granule membraneG-protein coupled receptor 84Homo sapiens (human)
tertiary granule membraneG-protein coupled receptor 84Homo sapiens (human)
receptor complexG-protein coupled receptor 84Homo sapiens (human)
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1546365Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546370Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay relative to embelin2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546364Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546369Displacement of [3H]PSB-1584 from recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 measured after 6 hrs by scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546366Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (18.37)18.7374
1990's8 (16.33)18.2507
2000's12 (24.49)29.6817
2010's18 (36.73)24.3611
2020's2 (4.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.65 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational2 (3.92%)0.25%
Other49 (96.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]